Primary Immunodeficiency (PID)

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

NCT01458171 | PHASE 3 | INTERVENTIONAL

The objective of this study is to assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06\_002CR (NCT01199705).

9 Sites

23 Participants

COMPLETED

to 75 Years

If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study site

Nagoya,Aichi Pref.,Japan,466-8560

Study site

Chiba,Chiba Pref.,Japan,260-8677

Study site

Fukuoka,Fukuoka,Japan,812-8582

Study site

Gifu,Gifu Pref.,Japan,502-8558

Study site

Sapporo,Hokkaido,Japan,060-8648

Study site

Moriguchi,Osaka,Japan,570-8507

Study site

Koshigaya,Saitama Pref.,Japan,343-8555

Study site

Tokorozawa,Saitama Pref.,Japan,359-8513

Study site

Bunkyō City,Tokyo Metropolitan,Japan,113-8519

Study Eligibility Criteria

Inclusion Criteria

* Subjects who have participated in study ZLB06\_002CR and who have tolerated IgPro20 well.
* Written informed consent by the subject/parent/legally acceptable representative. Written assent for an underage subject (≥7 years at the time of obtaining informed consent), as far as possible.

Exclusion Criteria

* Ongoing serious bacterial infections (SBIs) (pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess) at the time of the first infusion.
* Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (known total urine protein concentration \>0.2 g/L or urine protein ++ by dipstick).
* Pregnancy or nursing mother.
* Participation in a study with an investigational medicinal product (IMP) within 3 months prior to enrollment except for ZLB06\_002CR.
* Subjects who are planning to donate blood during the study.
* Re-entry of subjects previously participating in the current follow-up study.
* Known or suspected antibodies to the IMP, or to excipients of the IMP.

Additional Studies

Additional studies can be found at ClinicalTrials.gov